drugset / Trial / NCT05400109
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
Timeline
- Start
- 2023-04-26
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UF-KURE19 | Cell therapy | 6.5e+06 cells | — |
| Subject | UF-KURE19 | Cell therapy | 1e+07 cells | — |
| Subject | UF-KURE19 | Cell therapy | 1.15e+07 cells | — |
| Subject | UF-KURE19 | Cell therapy | 1.75e+07 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |